Physician profile
Amy J Baker
NPI 1043663396
$6,645.75
in general payments reported to CMS, 2019-2025
39 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 88% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,323 · 2022: $1,440 · 2023: $1,244 · 2024: $1,563 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,882.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,742.29 | 2021-2025 | |
| Novo Nordisk INC | $731.95 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $559.49 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Teva Pharmaceuticals USA, INC. | $447.12 | 2021-2024 | Ajovy, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $306.71 | 2021-2025 | Trintellix |
| Abbott Laboratories | $283.94 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $269.07 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $226.62 | 2021-2025 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.79 | 2022-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $204.82 | 2022 | |
| Supernus Pharmaceuticals, INC. | $204.31 | 2023-2024 | Qelbree, Qelbree |
| Medtronic, INC. | $132.27 | 2023-2025 | Venaseal, Mycarelink, Cobalt Dr Mri Surescan |
| Otsuka America Pharmaceutical, INC. | $114.95 | 2022-2025 | Rexulti |
| Pfizer INC. | $92.17 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.85 | 2024-2025 | Caplyta |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.91 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $83.75 | 2021-2023 | Xarelto |
| Axsome Therapeutics, INC. | $78.82 | 2024 | Auvelity |
| Eisai INC. | $76.40 | 2024-2025 | |
| Dexcom, INC. | $70.98 | 2024-2025 | Dexcom G6 Transmitter |
| Noven Therapeutics, LLC | $53.72 | 2023 | Xelstrym |
| Gilead Sciences, INC. | $52.42 | 2023-2025 | Trodelvy |
| Shield Therapeutics INC | $51.76 | 2025 | |
| Amarin Pharma, INC. | $47.66 | 2021 | |
| Merck Sharp & Dohme LLC | $46.07 | 2023 | Belsomra |
| Exact Sciences Corporation | $46.02 | 2023-2025 | Cologuard Collection Kit |
| Ardelyx, INC. | $38.94 | 2024 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $37.46 | 2021-2022 | |
| Glaxosmithkline, LLC. | $35.99 | 2024 | Trelegy Ellipta, Bexsero, Rotarix |
| Lundbeck LLC | $34.41 | 2023-2024 | Rexulti, Vyepti |
| Boston Scientific Corporation | $32.10 | 2025 | Watchman Flx |
| Astellas Pharma US INC | $29.78 | 2025 | Veozah |
| Genentech USA, INC. | $27.19 | 2021-2022 | |
| Organogenesis INC. | $25.89 | 2025 | Puraply Wound Matrix |
| Tris Pharma INC | $18.86 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.47 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $15.02 | 2023 | |
| Biogen, INC. | $14.13 | 2022 | |
| Vistapharm, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.